Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma.

Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, Bertalan M, Kaplan A, D'Andrea MR, Chukwueke U, Ippen FM, Alvarez-Breckenridge C, Camarda ND, Lastrapes M, McCabe D, Kuter B, Kaufman B, Strickland MR, Martinez-Gutierrez JC, Nagabhushan D, De Sauvage M, White MD, Castro BA, Hoang K, Kaneb A, Batchelor ED, Paek SH, Park SH, Martinez-Lage M, Berghoff AS, Merrill P, Gerstner ER, Batchelor TT, Frosch MP, Frazier RP, Borger DR, Iafrate AJ, Johnson BE, Santagata S, Preusser M, Cahill DP, Carter SL, Brastianos PK.

Nat Genet. 2020 Apr;52(4):371-377. doi: 10.1038/s41588-020-0592-7. Epub 2020 Mar 23.

PMID:
32203465
2.

'Real world' use of a highly reliable imaging sign: 'T2-FLAIR mismatch' for identification of IDH mutant astrocytomas.

Jain R, Johnson DR, Patel SH, Castillo M, Smits M, Bent MJVD, Chi AS, Cahill DP.

Neuro Oncol. 2020 Feb 17. pii: noaa041. doi: 10.1093/neuonc/noaa041. [Epub ahead of print]

PMID:
32064507
3.

Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.

Mirian C, Duun-Henriksen AK, Juratli T, Sahm F, Spiegl-Kreinecker S, Peyre M, Biczok A, Tonn JC, Goutagny S, Bertero L, Maier AD, Møller Pedersen M, Law I, Broholm H, Cahill DP, Brastianos P, Poulsgaard L, Fugleholm K, Ziebell M, Munch T, Mathiesen T.

J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):378-387. doi: 10.1136/jnnp-2019-322257. Epub 2020 Feb 10. Review.

PMID:
32041819
4.

Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.

Li X, Strasser B, Jafari-Khouzani K, Thapa B, Small J, Cahill DP, Dietrich J, Batchelor TT, Andronesi OC.

Radiology. 2020 Mar;294(3):589-597. doi: 10.1148/radiol.2020191529. Epub 2020 Jan 7.

PMID:
31909698
5.

A Multi-Institutional Analysis of Factors Influencing Surgical Outcomes for Patients with Newly Diagnosed Grade I Gliomas.

Yahanda AT, Patel B, Sutherland G, Honeycutt J, Jensen RL, Smyth MD, Limbrick DD Jr, Dacey RG Jr, Dowling JL, Dunn GP, Kim AH, Leuthardt EC, Rich KM, Zipfel GJ, Leonard JR, Cahill DP, Shah MV, Abram SR, Evans J, Tao Y, Chicoine MR.

World Neurosurg. 2020 Mar;135:e754-e764. doi: 10.1016/j.wneu.2019.12.156. Epub 2019 Dec 31.

PMID:
31901497
6.

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.

Higuchi F, Nagashima H, Ning J, Koerner MVA, Wakimoto H, Cahill DP.

Clin Cancer Res. 2020 Apr 1;26(7):1690-1699. doi: 10.1158/1078-0432.CCR-19-2000. Epub 2020 Jan 3.

PMID:
31900275
7.

Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas.

Williams SR, Juratli TA, Castro BA, Lazaro TT, Gill CM, Nayyar N, Strickland MR, Babinski M, Johnstone SE, Frosch MP, Silverman IM, Ely HA, Kaplan AB, D'Andrea MR, Bihun IV, Hoang K, Batchelor E, Christiansen J, Cahill DP, Barker FG 2nd, Brastianos PK.

J Neurol Surg B Skull Base. 2019 Dec;80(6):562-567. doi: 10.1055/s-0038-1676821. Epub 2019 Jan 10.

PMID:
31750041
8.

Neurologic complications of melanoma.

Cohen JV, Wang N, Venur VA, Hadfield MJ, Cahill DP, Oh K, Brastianos PK.

Cancer. 2020 Feb 1;126(3):477-486. doi: 10.1002/cncr.32619. Epub 2019 Nov 14. Review.

PMID:
31725902
9.

In Reply: A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.

Fujio S, Juratli TA, Cahill DP, Barker FG, Brastianos PK.

Neurosurgery. 2019 Nov 1;85(5):E966. doi: 10.1093/neuros/nyz327. No abstract available.

10.

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.

Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV.

Nat Biotechnol. 2019 Sep;37(9):1049-1058. doi: 10.1038/s41587-019-0192-1. Epub 2019 Jul 22.

PMID:
31332324
11.

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.

Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML.

Cell. 2019 Aug 8;178(4):835-849.e21. doi: 10.1016/j.cell.2019.06.024. Epub 2019 Jul 18.

PMID:
31327527
12.

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.

Juratli TA, Jones PS, Wang N, Subramanian M, Aylwin SJB, Odia Y, Rostami E, Gudjonsson O, Shaw BL, Cahill DP, Galanis E, Barker FG 2nd, Santagata S, Brastianos PK.

Cancer. 2019 Sep 1;125(17):2910-2914. doi: 10.1002/cncr.32197. Epub 2019 Jul 17. No abstract available.

PMID:
31314136
13.

A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma.

Nigim F, Kiyokawa J, Gurtner A, Kawamura Y, Hua L, Kasper EM, Brastianos PK, Cahill DP, Rabkin SD, Martuza RL, Carbonell WS, Wakimoto H.

Target Oncol. 2019 Aug;14(4):479-489. doi: 10.1007/s11523-019-00654-4.

PMID:
31301014
14.

Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.

Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, Mora JL, Nayyar N, Schmidt SP, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.

Neuro Oncol. 2019 Nov 4;21(11):1401-1411. doi: 10.1093/neuonc/noz105.

PMID:
31173106
15.

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?

Tom MC, Cahill DP, Buckner JC, Dietrich J, Parsons MW, Yu JS.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:133-145. doi: 10.1200/EDBK_238353. Epub 2019 May 17. Review.

16.

TERT Alterations in Progressive Treatment-Resistant Meningiomas.

Juratli TA, Brastianos PK, Cahill DP.

Neurosurgery. 2018 Sep 1;65(CN_suppl_1):66-68. doi: 10.1093/neuros/nyy154. No abstract available.

PMID:
31076787
17.

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.

Tanaka S, Batchelor TT, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, Yang D, Louis DN, Cahill DP, Chi AS.

Acta Neuropathol Commun. 2019 Apr 29;7(1):66. doi: 10.1186/s40478-019-0720-8.

18.

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.

Tateishi K, Nakamura T, Juratli TA, Williams EA, Matsushita Y, Miyake S, Nishi M, Miller JJ, Tummala SS, Fink AL, Lelic N, Koerner MVA, Miyake Y, Sasame J, Fujimoto K, Tanaka T, Minamimoto R, Matsunaga S, Mukaihara S, Shuto T, Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S, Curry WT, Dias-Santagata D, Yamamoto T, Ichimura K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H, Cahill DP.

Clin Cancer Res. 2019 Jul 15;25(14):4375-4387. doi: 10.1158/1078-0432.CCR-18-4144. Epub 2019 Apr 11.

PMID:
30975663
19.

Factors that modify the risk of intraoperative seizures triggered by electrical stimulation during supratentorial functional mapping.

Dineen J, Maus DC, Muzyka I, See RB, Cahill DP, Carter BS, Curry WT, Jones PS, Nahed BV, Peterfreund RA, Simon MV.

Clin Neurophysiol. 2019 Jun;130(6):1058-1065. doi: 10.1016/j.clinph.2019.03.006. Epub 2019 Mar 23.

PMID:
30930194
20.

Receptor tyrosine kinase gene amplification is predictive of intraoperative seizures during glioma resection with functional mapping.

Choi BD, Lee DK, Yang JC, Ayinon CM, Lee CK, Maus D, Carter BS, Barker FG, Jones PS, Nahed BV, Cahill DP, See RB, Simon MV, Curry WT.

J Neurosurg. 2019 Mar 29:1-7. doi: 10.3171/2018.12.JNS182700. [Epub ahead of print]

PMID:
30925466
21.

Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.

Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence DP, Flaherty KT, Shih HA, Oh K, Batchelor TT, Cahill DP, Sullivan R, Brastianos PK.

Oncologist. 2019 May;24(5):671-679. doi: 10.1634/theoncologist.2018-0306. Epub 2019 Feb 22.

22.

The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.

Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, Penson T, Schmidt SP, Wojtkiewicz GR, Ning J, Subramanian M, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.

Clin Cancer Res. 2019 Jun 1;25(11):3374-3383. doi: 10.1158/1078-0432.CCR-18-3049. Epub 2019 Feb 22.

PMID:
30796030
23.

MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.

Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, D'Andrea MR, Bihun I, Kaneb A, Dietrich J, Ferry JA, Martinez-Lage M, Giobbie-Hurder A, Borger DR, Rodriguez FJ, Frosch MP, Batchelor E, Hoang K, Kuter B, Fortin S, Holdhoff M, Cahill DP, Carter S, Brastianos PK, Batchelor TT.

Blood Adv. 2019 Feb 12;3(3):375-383. doi: 10.1182/bloodadvances.2018027672.

24.

Performance of a Hospital Pathway for Patients With a New Single Brain Mass.

Arrillaga-Romany I, Curry WT Jr, Jordan JT, Cahill DP, Nahed BV, Martuza RL, Loeffler JS, Järhult SJ, Muzikansky A, Cohen AB, Singhal AB, Goldstein JN, Batchelor TT.

J Oncol Pract. 2019 Mar;15(3):e211-e218. doi: 10.1200/JOP.17.00098. Epub 2019 Jan 25.

PMID:
30681891
25.

Accelerated progression of IDH mutant glioma after first recurrence.

Miller JJ, Loebel F, Juratli TA, Tummala SS, Williams EA, Batchelor TT, Arrillaga-Romany I, Cahill DP.

Neuro Oncol. 2019 May 6;21(5):669-677. doi: 10.1093/neuonc/noz016.

PMID:
30668823
26.

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.

Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H.

Sci Rep. 2019 Jan 15;9(1):139. doi: 10.1038/s41598-018-37437-2.

27.

Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.

Juratli TA, Tummala SS, Riedl A, Daubner D, Hennig S, Penson T, Zolal A, Thiede C, Schackert G, Krex D, Miller JJ, Cahill DP.

J Neurooncol. 2019 Jan;141(2):327-335. doi: 10.1007/s11060-018-03034-6. Epub 2018 Dec 7.

28.

Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.

Bale TA, Jordan JT, Rapalino O, Ramamurthy N, Jessop N, DeWitt JC, Nardi V, Alvarez MM, Frosch M, Batchelor TT, Louis DN, Iafrate AJ, Cahill DP, Lennerz JK.

Neuro Oncol. 2019 May 6;21(5):596-605. doi: 10.1093/neuonc/noy201.

PMID:
30496526
29.

A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.

Fujio S, Juratli TA, Arita K, Hirano H, Nagano Y, Takajo T, Yoshimoto K, Bihun IV, Kaplan AB, Nayyar N, Fink AL, Bertalan MS, Tummala SS, Curry WT Jr, Jones PS, Martinez-Lage M, Cahill DP, Barker FG, Brastianos PK.

Neurosurgery. 2019 Aug 1;85(2):204-210. doi: 10.1093/neuros/nyy569.

PMID:
30481321
30.

Extent of Resection Versus Molecular Classification: What Matters When?

Clark VE, Cahill DP.

Neurosurg Clin N Am. 2019 Jan;30(1):95-101. doi: 10.1016/j.nec.2018.08.006. Review.

PMID:
30470409
31.

Updates in prognostic markers for gliomas.

Aquilanti E, Miller J, Santagata S, Cahill DP, Brastianos PK.

Neuro Oncol. 2018 Nov 9;20(suppl_7):vii17-vii26. doi: 10.1093/neuonc/noy158.

32.

Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.

Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara CM, Frenster JD, Tateishi K, Wakimoto H, Jain R, Riina HA, Nicolaides TP, Sulman EP, Cahill DP, Golfinos JG, Isse K, Saunders LR, Zagzag D, Placantonakis DG, Snuderl M, Chi AS.

Clin Cancer Res. 2019 Feb 15;25(4):1261-1271. doi: 10.1158/1078-0432.CCR-18-2312. Epub 2018 Nov 5.

33.

TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.

Williams EA, Miller JJ, Tummala SS, Penson T, Iafrate AJ, Juratli TA, Cahill DP.

Acta Neuropathol Commun. 2018 Oct 17;6(1):106. doi: 10.1186/s40478-018-0613-2.

34.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN.

Cancer Discov. 2018 Dec;8(12):1598-1613. doi: 10.1158/2159-8290.CD-18-0277. Epub 2018 Sep 25.

35.

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma.

McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG, Kaelin WG Jr.

Cell. 2018 Sep 20;175(1):101-116.e25. doi: 10.1016/j.cell.2018.08.038. Epub 2018 Sep 13.

36.

PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.

Higuchi F, Fink AL, Kiyokawa J, Miller JJ, Koerner MVA, Cahill DP, Wakimoto H.

Mol Cancer Ther. 2018 Dec;17(12):2551-2563. doi: 10.1158/1535-7163.MCT-18-0177. Epub 2018 Sep 14.

37.

The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study.

Ding X, Wang Z, Chen D, Wang Y, Zhao Z, Sun C, Chen D, Tang C, Xiong J, Chen L, Yao Z, Liu Y, Wang X, Cahill DP, de Groot JF, Jiang T, Yao Y, Zhou L.

J Neurooncol. 2018 Dec;140(3):591-603. doi: 10.1007/s11060-018-2985-3. Epub 2018 Sep 11.

PMID:
30206763
38.

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.

Yuan AL, Ricks CB, Bohm AK, Lun X, Maxwell L, Safdar S, Bukhari S, Gerber A, Sayeed W, Bering EA, Pedersen H, Chan JA, Shen Y, Marra M, Kaplan DR, Mason W, Goodman LD, Ezhilarasan R, Kaufmann AB, Cabral M, Robbins SM, Senger DL, Cahill DP, Sulman EP, Cairncross JG, Blough MD.

PLoS One. 2018 Aug 28;13(8):e0202860. doi: 10.1371/journal.pone.0202860. eCollection 2018.

39.

DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.

Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG 2nd, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK.

Acta Neuropathol. 2018 Nov;136(5):779-792. doi: 10.1007/s00401-018-1899-7. Epub 2018 Aug 19.

PMID:
30123936
40.

Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study.

Ly KI, Oakley DH, Pine AB, Frosch MP, Chiou SH, Betensky RA, Pomerantz SR, Hochberg FH, Batchelor TT, Cahill DP, Dietrich J.

Oncologist. 2019 Mar;24(3):402-413. doi: 10.1634/theoncologist.2018-0086. Epub 2018 Aug 10.

41.

Genotype-targeted local therapy of glioma.

Shankar GM, Kirtane AR, Miller JJ, Mazdiyasni H, Rogner J, Tai T, Williams EA, Higuchi F, Juratli TA, Tateishi K, Koerner MVA, Tummala SS, Fink AL, Penson T, Schmidt SP, Wojtkiewicz GR, Baig A, Francis JM, Rinne ML, Batten JM, Batchelor TT, Brastianos PK, Curry WT Jr, Barker FG 2nd, Jordan JT, Iafrate AJ, Chi AS, Lennerz JK, Meyerson M, Langer R, Wakimoto H, Traverso G, Cahill DP.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8388-E8394. doi: 10.1073/pnas.1805751115. Epub 2018 Aug 6.

42.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.

Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9.

PMID:
29988124
43.

Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens.

Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D'Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Frosch MP, Suva ML, Cahill DP, Getz G, Batchelor TT.

NPJ Precis Oncol. 2017 Sep 18;1(1):33. doi: 10.1038/s41698-017-0035-9. eCollection 2017.

44.

Isocitrate Dehydrogenase Mutations in Low-Grade Gliomas Correlate With Prolonged Overall Survival in Older Patients.

Jones PS, Carroll KT, Koch M, DiCesare JAT, Reitz K, Frosch M, Barker FG 2nd, Cahill DP, Curry WT Jr.

Neurosurgery. 2019 Feb 1;84(2):519-528. doi: 10.1093/neuros/nyy149.

PMID:
29846690
45.

Neural encoding and production of functional morphemes in the posterior temporal lobe.

Lee DK, Fedorenko E, Simon MV, Curry WT, Nahed BV, Cahill DP, Williams ZM.

Nat Commun. 2018 May 14;9(1):1877. doi: 10.1038/s41467-018-04235-3.

46.

Malignant Melanoma Metastatic to Oligodendroglioma: Case Report and Literature Review of Tumor-to-Tumor Metastasis to Gliomas.

Giantini Larsen A, Grannan BL, Lee CK, Koch MJ, Williams EA, Frosch MP, Cahill DP.

J Neuropathol Exp Neurol. 2018 Jul 1;77(7):549-554. doi: 10.1093/jnen/nly029.

PMID:
29746652
47.

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.

Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP, Batchelor TT.

Nat Commun. 2018 Apr 16;9(1):1474. doi: 10.1038/s41467-018-03905-6.

48.

Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas.

Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, Williams EA, Martinez-Lage M, Soucek S, Robel K, Penson T, Krause M, Appold S, Meinhardt M, Pinzer T, Miller JJ, Krex D, Ely HA, Silverman IM, Christiansen J, Schackert G, Wakimoto H, Kirsch M, Brastianos PK, Cahill DP.

Oncotarget. 2017 Nov 24;8(65):109228-109237. doi: 10.18632/oncotarget.22650. eCollection 2017 Dec 12.

49.

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.

Miller JJ, Shih HA, Andronesi OC, Cahill DP.

Cancer. 2017 Dec 1;123(23):4535-4546. doi: 10.1002/cncr.31039. Epub 2017 Oct 5. Review.

50.

Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.

Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, Neupane R, Fenoglio S, Cahill DP, Wakimoto H, Agar NYR, Yaffe MB, Sharp PA, Hemann MT, Lees JA.

Cancer Cell. 2017 Oct 9;32(4):411-426.e11. doi: 10.1016/j.ccell.2017.08.018. Epub 2017 Sep 28.

Supplemental Content

Loading ...
Support Center